• BioMimetic Therapeutics (Franklin, Tennessee) reports positive results from its pilot clinical study evaluating the safety and clinical utility of GEM OS1 Bone Graft for the treatment of distal radius (wrist) fractures. In the study, evaluating distal radius fractures treated with external fixation versus external fixation augmented with GEM OS1, patients treated with GEM OS1 demonstrated faster bone healing at the fracture site as measured by CT scans. The company also reported that it has initiated patient enrollment in a pilot study evaluating its second orthopedic product candidate, GEM OS2 Injectable Bone Graft, for the closed treatment of distal radius fractures. GEM OS1 is indicated for use in open surgical procedures while GEM OS2 is indicated primarily for minimally invasive, percutaneous administration to a fracture site without surgical intervention. BioMimetic makes bio-active drug-device combination products for the healing of musculoskeletal injuries and disease, including periodontal, orthopedic, spine and sports injury applications.

• DePuy Spine (Raynham, Massachusetts), a Johnson & Johnson company, reported the launch of the Expedium 6.35, a titanium and stainless steel screw and rod system designed to simplify the correction of spinal deformities and treatment for degenerative disc disease. The System’s screws are designed with a double-lead thread pattern allowing surgeons to advance the screws twice as fast as standard screws. The system includes screw options, open and closed hook patterns, multiple rod-to-rod connection options and lateral connectors. DePuy Spine makes products to treat spine disorders.

• Molecular Devices (Sunnyvale, California) reported the introduction of the Arcturus laser capture microdissection instrument. The instrument employs Molecular Devices’ LCM technology and, combined with the system’s automated image archiving, enables researchers to maintain sample custody at all times. Molecular Devices is a supplier of bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research.

• Nymox Pharmaceutical (Hasbrouck Heights, New Jersey) reports the publication of a new peer-reviewed report in the Journal of Clinical Laboratory Analysis providing further positive data on the accuracy and utility of the company’s urinary AlzheimAlert test. AlzheimAlert is Nymox’s urine-based diagnostic aid for Alzheimer’s disease. The test has the CE Mark, allowing it to be marketed in Europe, and is also available to physicians in the U.S. Nymox is a biopharmaceutical company specializing in the research and development of therapeutics and diagnostics for the aging population.